What is Navinci Holdings?
Navinci Holdings is a Swedish biotechnology firm specializing in advanced in situ proximity ligation assay (PLA) solutions for spatial proteomics. The company's proprietary technology enables precise detection of proteins, protein-protein interactions, and modifications within various sample types, including cultured cells and FFPE samples. By offering flexible and target-specific kits powered by Navenibodies, Navinci aims to accelerate scientific discovery and provide researchers with cutting-edge tools for detailed protein analysis.
How much funding has Navinci Holdings raised?
Navinci Holdings has raised a total of $8.5M across 1 funding round:
Series A
$8.5M
Series A (2022): $8.5M with participation from Landegren Gene Technology AB, Nexttobe AB, and Segulah Medical Acceleration
Key Investors in Navinci Holdings
Landegren Gene Technology AB
Landegren Gene Technology AB is an investor with a focus on gene technology, likely supporting companies advancing molecular diagnostics and research tools.
Nexttobe AB
Nexttobe AB is an investment entity that appears to back innovative companies, potentially within the life sciences or technology sectors.
Segulah Medical Acceleration
Segulah Medical Acceleration is a venture capital firm specializing in the medical technology and life sciences sectors, providing strategic backing for companies with high growth potential.
What's next for Navinci Holdings?
The substantial enterprise-level funding, including the recent major strategic investment, positions Navinci Holdings for accelerated growth and market expansion. This capital infusion is expected to fuel further development of their innovative spatial proteomics solutions, enhance research and development capabilities, and potentially broaden their global reach. The company's focus on empowering researchers suggests a strategy geared towards solidifying its position as a leader in advanced diagnostics and life science research tools.
See full Navinci Holdings company page
